SML3925

Liraglutide

≥95% (HPLC)

• 别名: Arg34, Lys26-[Nε(γ-Glu[Nα-hexadecanoyl])]-GLP-1[7-37], H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-Lys-α-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH, HAEGTFTSDVSSYLEGQAA-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]K-EFIAWLVRGRG, NN2211
• 经验公式（希尔记法）: C₁₇₂H₂₆₅N₄₃O₅₁
• CAS号: 204656-20-2
• 分子量: 3751.20
• 分類程式碼代碼: 51111800
• 分類程式碼代碼: 12352200
• NACRES: NA.77

属性

• 品質等級: 100
• 化驗: ≥95% (HPLC)
• 形狀: (Powder or Lyophilized powder or film)
• 顏色: white to off-white
• 儲存溫度: -10 to -25°C

说明

生化／生理作用

Glucagon-like peptide-1 (GLP-1)-based incretin mimetic with enhanced in vivo stability and efficacy against type 2 diabetes and obesity.

Liraglutide (NN2211) is a glucagon-like peptide-1 (GLP-1)-based incretin mimetic (cAMP stimulation EC50 = 61 nM vs 55 nM with GLP-1(7-37) using human GLP-1 receptor-expressing BHK cells), where GLP-1(7-37) sequence is modified with a Lys34-to-Arg substitution and a γ-Glu-C16 acylation on Lys26 for enhanced in vivo stability (plasma t1/2 in pigs post s.c. = 14 h vs 1.2 h with GLP-1(7-37)) and efficacy against type 2 diabetes and obesity (400 μg/kg/day s.c. in rats; 100-200 μg/kg bid or single 50-200 μg/kg i.v. in rats; 100 μg/kg bid or single 30-1000 μg/kg s.c. in mice; 2 μg/kg i.v. or 3.3 μg/kg/day s.c. in pigs).

安全信息

• 象形圖: GHS08
• 訊號詞: Warning
• 危險聲明: H361d
• 防範說明: P201 - P202 - P280 - P308 + P313 - P405 - P501
• 危險分類: Repr. 2
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3